Terence Flynn
Stock Analyst at Morgan Stanley
(3.86)
# 653
Out of 4,966 analysts
200
Total ratings
59.8%
Success rate
6.73%
Average return
Main Sectors:
Stocks Rated by Terence Flynn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALMS Alumis | Maintains: Overweight | $23 → $22 | $4.64 | +374.14% | 2 | Aug 15, 2025 | |
| BHVN Biohaven | Maintains: Overweight | $63 → $54 | $15.39 | +250.88% | 3 | Aug 12, 2025 | |
| PFE Pfizer | Maintains: Equal-Weight | $32 → $33 | $24.76 | +33.28% | 18 | Aug 6, 2025 | |
| AMGN Amgen | Maintains: Equal-Weight | $330 → $333 | $287.71 | +15.74% | 9 | Aug 6, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $255 | $210.40 | +21.20% | 17 | Aug 1, 2025 | |
| JNJ Johnson & Johnson | Maintains: Equal-Weight | $171 → $176 | $177.17 | -0.66% | 23 | Jul 17, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Equal-Weight | $17 → $16 | $9.34 | +71.31% | 5 | Jul 15, 2025 | |
| RPRX Royalty Pharma | Maintains: Overweight | $51 → $54 | $35.98 | +50.08% | 12 | Jul 10, 2025 | |
| MRK Merck & Co. | Maintains: Equal-Weight | $99 → $98 | $84.12 | +16.50% | 17 | Jul 10, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Underweight | $36 → $34 | $47.18 | -27.94% | 11 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $132 → $133 | $100.00 | +33.00% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,133 → $1,135 | $732.58 | +54.93% | 20 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $348 → $328 | $304.76 | +7.63% | 10 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $12 → $11 | $7.73 | +42.30% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $22 | $10.59 | +107.74% | 6 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $10 | $9.42 | +6.16% | 10 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $30 → $32 | $51.83 | -38.26% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $56 → $11 | $11.36 | -3.13% | 5 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $118 | $19.30 | +511.40% | 1 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1 → $8 | $2.60 | +207.69% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $246 → $436 | $132.22 | +229.75% | 3 | Jun 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $446.51 | - | 2 | Oct 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.83 | - | 1 | Jul 21, 2017 |
Alumis
Aug 15, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $4.64
Upside: +374.14%
Biohaven
Aug 12, 2025
Maintains: Overweight
Price Target: $63 → $54
Current: $15.39
Upside: +250.88%
Pfizer
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $32 → $33
Current: $24.76
Upside: +33.28%
Amgen
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $330 → $333
Current: $287.71
Upside: +15.74%
AbbVie
Aug 1, 2025
Maintains: Overweight
Price Target: $250 → $255
Current: $210.40
Upside: +21.20%
Johnson & Johnson
Jul 17, 2025
Maintains: Equal-Weight
Price Target: $171 → $176
Current: $177.17
Upside: -0.66%
Nurix Therapeutics
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $9.34
Upside: +71.31%
Royalty Pharma
Jul 10, 2025
Maintains: Overweight
Price Target: $51 → $54
Current: $35.98
Upside: +50.08%
Merck & Co.
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $99 → $98
Current: $84.12
Upside: +16.50%
Bristol-Myers Squibb Company
Jul 10, 2025
Maintains: Underweight
Price Target: $36 → $34
Current: $47.18
Upside: -27.94%
Jul 10, 2025
Maintains: Overweight
Price Target: $132 → $133
Current: $100.00
Upside: +33.00%
Jul 10, 2025
Maintains: Overweight
Price Target: $1,133 → $1,135
Current: $732.58
Upside: +54.93%
Jul 10, 2025
Maintains: Equal-Weight
Price Target: $348 → $328
Current: $304.76
Upside: +7.63%
May 9, 2025
Maintains: Equal-Weight
Price Target: $12 → $11
Current: $7.73
Upside: +42.30%
May 9, 2025
Maintains: Overweight
Price Target: $24 → $22
Current: $10.59
Upside: +107.74%
May 5, 2025
Maintains: Equal-Weight
Price Target: $15 → $10
Current: $9.42
Upside: +6.16%
Feb 14, 2025
Maintains: Underweight
Price Target: $30 → $32
Current: $51.83
Upside: -38.26%
Jan 27, 2025
Downgrades: Equal-Weight
Price Target: $56 → $11
Current: $11.36
Upside: -3.13%
Sep 23, 2024
Initiates: Overweight
Price Target: $118
Current: $19.30
Upside: +511.40%
Feb 26, 2024
Maintains: Equal-Weight
Price Target: $1 → $8
Current: $2.60
Upside: +207.69%
Jun 14, 2021
Maintains: Neutral
Price Target: $246 → $436
Current: $132.22
Upside: +229.75%
Oct 2, 2017
Upgrades: Buy
Price Target: n/a
Current: $446.51
Upside: -
Jul 21, 2017
Downgrades: Neutral
Price Target: n/a
Current: $11.83
Upside: -